Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.

Gutner, Cassidy A;van der Valk, Marc;Portilla, Joaquin;Jeanmaire, Eliette;Czarnogorski, Maggie;et.al.
(2024) Journal of the International Association of Providers of AIDS Care — Vol. 23, p. 23259582241269837 (2024)

Files

2024_Gutner_J_Int_Assoc_Provid_AIDS_Care.pdf
  • Open Access
  • Adobe PDF
  • 1.64 MB
  • https://creativecommons.org/licenses/by-nc/4.0/
Download

Details

Authors
  • Gutner, Cassidy A
    Author
  • van der Valk, Marc
    Author
  • Portilla, Joaquin
    Author
  • Jeanmaire, Eliette
    Author
  • Belkhir, Leïlaorcid-logoUCLouvain
    Author
  • Czarnogorski, Maggie
    Author
Show more
Abstract
INTRODUCTION: CARISEL is an implementation-effectiveness "hybrid" study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries. METHODS: PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted. RESULTS: Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores ≥4.47/5). Qualitative data supported these observations. CONCLUSIONS: PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Gutner, C. A., van der Valk, M., Portilla, J., Jeanmaire, E., Belkhir, L., Lutz, T., DeMoor, R., Trehan, R., Scherzer, J., Pascual-Bernáldez, M., Ait-Khaled, M., Hernandez, B., de Ruiter, A., Anand, S. B., Low, E. L., Hadi, M., Barnes, N., Sevdalis, N., Mohammed, P., & Czarnogorski, M. (2024). Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study. Journal of the International Association of Providers of AIDS Care, 23, 23259582241269837. https://doi.org/10.1177/23259582241269837 (Original work published 2024)